Company news

MetaVia Inc. news in 2023

MetaVia Inc.'s news releases, calls and decks from 2023, newest first.

View company

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

December 27, 2023

NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

December 18, 2023

NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023

NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.

November 5, 2023

NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference

October 16, 2023

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

September 14, 2023

NeuroBo pharmaceuticals appoints hyung heon Kim as Chief Executive Officer and President

August 13, 2023

NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 8, 2023

NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

August 2, 2023

NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01

August 1, 2023

NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models

June 26, 2023

NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors

May 11, 2023

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

May 1, 2023

NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results

March 29, 2023

NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President

January 17, 2023

Decks in 2023